The efficacy and the tolerance of postoperative radiochemotherapy in gastric cancer

Ciepiela, Izabela; Kędzierawski, Piotr; Florek, Agnieszka; Góźdż, Stanisław; Mężyk, Ryszard

doi:10.5114/wo.2010.14133

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy is a treatment modality that is frequently combined with chemotherapy in the so-called chemoradiotherapy. After the American SWOG/INT0116 clinical trial, radiotherapy currently constitutes a standard treatment strategy just after the radical gastrectomy in many Oncological Units [96,97]. However, radiotherapy is also developed as a palliative, first in the 1960s, and adjuvant to neoadjuvant treatment of GC [78,98].…”

Section: Radiotherapymentioning

confidence: 99%

Treatment Strategies of Gastric Cancer—Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review

Tyczyńska

Kędzierawski

Karakuła

et al. 2021

J Gastrointest Canc

View full text Add to dashboard Cite

Purpose Recent studies have suggested that molecular targets for the anti-angiogenic therapy might constitute a basis for additional therapy in gastric cancer treatment. A vast number of molecules, receptors, pathways, specific interactions, and thus strategies that target gastric cancer angiogenesis specifically have been reported in numerous research articles and clinical trials. Methods We conducted a systematic literature review of molecularly targeted treatment strategies in gastric cancer on the following databases—PubMed, Google Scholar, and Scopus—on September 20, 2020. Multiple articles and evaluations were searched for studies reporting newly found and promising molecular anti-angiogenic therapy pathways. Eventually, 39 articles regarding the anti-angiogenic therapy in gastric cancer were included in the final analysis. Results As a consequence of the release of the pro-angiogenic molecules from the tumour cells, gastric cancer presents high angiogenic capability. Therefore, potential schemes for future treatment strategies include the decrease of the process ligands as well as the expression of their receptors. Moreover, the increase in the angiogenic inhibitor levels and direct aim for the inner walls of the endothelial cells appear as a promising therapeutic strategy. Beyond that, angiogenesis process inhibition seems to indirectly exaggerate the effects of chemotherapy in the considered patients. Conclusions The anti-angiogenic treatment in gastric cancer patients evaluates its significance especially in the early stages of the malignancy. The studies conducted so far show that most of the meaningful angiogenic factors and receptors with the potential molecular pathways should be further evaluated since they could potentially play a substantial role in future therapies.

show abstract